reviews are not done to assess the efficacy of a specific intervention. Selected retrospective case reviews performed by independent groups not involved in the treatment of the patients are subject to many potential biases, which make it inappropriate to draw such conclusions.
At the completion of the reviews, the NCI's Office of Cancer Complementary and Alternative Medicine uses an internal classification system and labels the cases as "unevaluable," "supportive," or "persuasive." The terminology is used to categorize the strength of a case and thus its utility in making an argument in favor of NCI-initiated research. An unevaluable case would be one lacking important information or criteria including, but not limited to, confirmation of disease by pathology, precise case history, and/or radiological imaging. An example of a supportive case is one that meets the criteria but with stable disease as the best response. Finally, a persuasive case could be defined as one that meets all basic criteria of the NCI BCS program and tumor response is at least a PR. We do not require a CR for the designation of "persuasive" as indicated in the article by Yoo et al.
The authors state that "the BCS program has provided a means of standardizing the review of documentation in support of the use of CAM modalities in the treatment of patients with cancer." This is not the intent of the NCI BCS program. Our goal is to evaluate retrospective case reports and assess the quality of available data and its utility as support for the justification of NCI-initiated research. We do not evaluate a treatment for its effectiveness, which is done by analyzing the results of welldesigned clinical trials. Therefore, our program does not "support the use of CAM (complementary and alternative modalities) in the treatment of patients with cancer," as stated by the authors.
The authors present the challenge of locating pathology slides of metastatic disease sites. They suggest that the NCI BCS program should consider accepting diagnostic images in cases where pathology is unavailable for the recurrence or metastasis. We acknowledge the challenge; however, if the metastatic disease is the target lesion being monitored for response, pathology confirming cancer allows a greater confidence in the significance of the case, as well as the designation of "persuasive" versus "supportive," given that other criteria are also fulfilled. Furthermore, various studies have established the importance of biopsy to establish a diagnosis in the oncological setting. In Although the authors correctly capture the meticulous submission process, there are points that need to be addressed. The authors state in the introduction that a "persuasive case is one that has pathology confirmed by the National Institutes of Health (NIH) and radiographic response resulting in complete remission." A supportive case is defined by Yoo et al as a case with "NIH confirmed pathology and radiographic response resulting in partial response or stable disease." Because the NCI BCS program reviews are performed in our office, we would like to clarify that point by describing our evaluation system.
Cases are initially evaluated for 4 criteria. First, there must be a definitive diagnosis of cancer, necessitating either a tissue biopsy or fine needle aspiration for solid tumors. Second, because objective tumor response is the primary endpoint of the NCI BCS program, only patients with detectable residual disease at baseline can be assessed. Third, the patient should not have received either concurrent or recent treatment with conventional anticancer therapy. If conventional treatment was administered, at least 4 weeks should have elapsed prior to the start of the alternative regimen. Finally, there should be documentation that the patient received the alternative intervention.
Cases that meet these criteria are further assessed. The pathological diagnosis is confirmed by an NIH pathologist. Likewise, the radiological response is assessed by an NIH radiologist. Objective tumor response by the RECIST criteria is evaluated. Thus, a partial response (PR) would be at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) would be at least a 20% increase in the sum of the LD of target lesions, stable disease would be neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, and complete response (CR) is defined as disappearance of all target lesions. 2 Although these assessments are made, it is not with the intention of directly attributing the "response" to the alternative intervention. The NCI BCS program's retrospective with non-small cell lung cancer (NSCLC) were retrospectively analyzed by a radiologist and a decision made about whether certain lymph nodes appeared malignant or benign. The decision was based on size and other radiological criteria. This was then compared with the postoperative histopathologic result. The independent radiological evaluation of the CT scans of 80 patients yielded a sensitivity of 57.1% and a specificity of 80.6%. The study concluded that evaluation of lymph nodes via radiological criteria, including size, was not reliable for the evaluation of metastatic involvement in patients with NSCLC. Similarly, in 1994, Arbit and Galicich 4 reported a study in which the records of 100 consecutive stereotactic brain biopsies were postoperatively reviewed. In 19% of patients, the clinical and histological diagnoses differed. In certain instances, the tissue diagnosis turned out to be radiationinduced necrosis, inflammation, or infection. Thus, the authors concluded that reliance on brain imaging alone would have lead to an incorrect diagnosis and the wrong choice of treatment in those cases.
Indeed, the candid discussion of the NCI BCS program presented by Yoo et al captures the challenges faced by CAM institutions and providers in the submission and review process. Although we are sensitive to the issues raised by the authors, our program goal necessitates a consistent adherence to these rigorous criteria. Determination of the utility of further NCI-initiated research relies on objective rather than purely subjective measures. Pathological diagnosis of the target lesion, along with appropriate radiological imaging indicating stability, regression, or progression in response to the alternative regimen, are key objective components of the decision-making process. We hope that potential submitters may realize the challenges faced by our program in maintaining rigorous standards in an area of medicine that is infrequently objectively assessed. To that end, we encourage submissions and are committed to the identification of alternative approaches that meet these standards and thus can be prospectively researched by NCI.
